[go: up one dir, main page]

WO2006059169A2 - Nouvelle composition pharmaceutique antivirale et immunostimulante - Google Patents

Nouvelle composition pharmaceutique antivirale et immunostimulante Download PDF

Info

Publication number
WO2006059169A2
WO2006059169A2 PCT/HU2005/000122 HU2005000122W WO2006059169A2 WO 2006059169 A2 WO2006059169 A2 WO 2006059169A2 HU 2005000122 W HU2005000122 W HU 2005000122W WO 2006059169 A2 WO2006059169 A2 WO 2006059169A2
Authority
WO
WIPO (PCT)
Prior art keywords
mass
polyunsaturated fatty
fatty acid
lysine
selenium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2005/000122
Other languages
English (en)
Other versions
WO2006059169A3 (fr
Inventor
Jenö SZILBEREKY
Andrea JEDNÁKOVITS
Ernöné KOLTAI
Gyula Orbán
Katalin BÍRÓ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinnex Mueszaki Fejleszto Es Tanacsado Kft
Original Assignee
Sinnex Mueszaki Fejleszto Es Tanacsado Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinnex Mueszaki Fejleszto Es Tanacsado Kft filed Critical Sinnex Mueszaki Fejleszto Es Tanacsado Kft
Priority to AT05808584T priority Critical patent/ATE429236T1/de
Priority to EP05808584A priority patent/EP1830861B1/fr
Priority to CN200580041636XA priority patent/CN101068540B/zh
Priority to PL05808584T priority patent/PL1830861T3/pl
Priority to US11/792,247 priority patent/US9381213B2/en
Priority to DE602005014142T priority patent/DE602005014142D1/de
Priority to JP2007543938A priority patent/JP4976307B2/ja
Priority to CA2588195A priority patent/CA2588195C/fr
Priority to DK05808584T priority patent/DK1830861T3/da
Publication of WO2006059169A2 publication Critical patent/WO2006059169A2/fr
Publication of WO2006059169A3 publication Critical patent/WO2006059169A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • Tissue secondary monkey kidney cell culture, cell number: 5x10 6 .
  • Example 1 contains a mixture of ⁇ -3-polyunsaturated fatty acid ethyl esters (362 g) composed of 32.8 mass% of 5,8,11,14,17-eicosapentaenic acid ethyl (EPA ethyl ester), and 22.2 mass% of 4,7,10,13, 16,19-docosahexaenic acid ethyl ester (DHA ethyl ester), and the active ingredients and additives specified in Example 1 but is also supplemented with selenium incorporated into natural yeast (1 g).
  • EPA ethyl ester 3,5,14,17-eicosapentaenic acid ethyl
  • DHA ethyl ester 4,7,10,13, 16,19-docosahexaenic acid ethyl ester

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle composition pharmaceutique antivirale et immunostimulante, contenant, comme ingrédient actif, 20 à 85 % en masse d'un ester d'acide gras polyinsaturé oméga 3, dans un concentré d'huile de poisson contenant 20 à 70 % en masse d'un ester d'acide 5,8,11,14,17-eicosapentanoïque et d'un ester d'acide 4,7,10, 13, 16, 19-docosahexanoïque, de la l-lysine ou un de ses sels, éventuellement du sel de zinc, du sélénium ou un composé de sélénium, ainsi que des additifs et des excipients.
PCT/HU2005/000122 2004-12-03 2005-11-15 Nouvelle composition pharmaceutique antivirale et immunostimulante Ceased WO2006059169A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT05808584T ATE429236T1 (de) 2004-12-03 2005-11-15 Antivirale und immunstimulierende meeresfischölzusammensetzung
EP05808584A EP1830861B1 (fr) 2004-12-03 2005-11-15 Nouvelle composition pharmaceutique antivirale et immunostimulante
CN200580041636XA CN101068540B (zh) 2004-12-03 2005-11-15 抗病毒性和免疫刺激性海鱼油组合物
PL05808584T PL1830861T3 (pl) 2004-12-03 2005-11-15 Antywirusowa i immunostymulująca kompozycja oleju z ryb morskich
US11/792,247 US9381213B2 (en) 2004-12-03 2005-11-15 Antiviral and immune stimulant pharmaceutical composition
DE602005014142T DE602005014142D1 (de) 2004-12-03 2005-11-15 Antivirale und immunstimulierende meeresfischölzusammensetzung
JP2007543938A JP4976307B2 (ja) 2004-12-03 2005-11-15 新規な抗ウイルス性および免疫刺激性の医薬組成物
CA2588195A CA2588195C (fr) 2004-12-03 2005-11-15 Nouvelle composition pharmaceutique antivirale et immunostimulante
DK05808584T DK1830861T3 (da) 2004-12-03 2005-11-15 Antiviralt og immunstimulerende havfiskeoliepræparat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0402490 2004-12-03
HU0402490A HU227588B1 (hu) 2004-12-03 2004-12-03 Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény

Publications (2)

Publication Number Publication Date
WO2006059169A2 true WO2006059169A2 (fr) 2006-06-08
WO2006059169A3 WO2006059169A3 (fr) 2007-02-22

Family

ID=89985663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2005/000122 Ceased WO2006059169A2 (fr) 2004-12-03 2005-11-15 Nouvelle composition pharmaceutique antivirale et immunostimulante

Country Status (13)

Country Link
US (1) US9381213B2 (fr)
EP (1) EP1830861B1 (fr)
JP (1) JP4976307B2 (fr)
KR (1) KR101263963B1 (fr)
CN (1) CN101068540B (fr)
AT (1) ATE429236T1 (fr)
CA (1) CA2588195C (fr)
DE (1) DE602005014142D1 (fr)
DK (1) DK1830861T3 (fr)
ES (1) ES2326091T3 (fr)
HU (1) HU227588B1 (fr)
PL (1) PL1830861T3 (fr)
WO (1) WO2006059169A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073176A3 (fr) * 2005-12-23 2008-09-12 Nutricia Nv Composition permettant d'ameliorer la composition membranaire et le fonctionnement des cellules
EP3248467A1 (fr) * 2016-05-25 2017-11-29 Evonik Technochemie GmbH Procede de production d'une composition contenant des sels lysine-l-acides gras-omega 3
US20240148683A1 (en) * 2009-04-29 2024-05-09 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
EP4192483A4 (fr) * 2020-08-10 2024-08-21 Houn Simon Hsia Compositions et méthodes de traitement d'infection virale

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5710150B2 (ja) * 2010-04-08 2015-04-30 持田製薬株式会社 潜伏性感染疾患の再発抑制剤
JP2012149000A (ja) * 2011-01-18 2012-08-09 Junsei Educational Institution 免疫賦活剤ならびにこれを含む食品および医薬組成物
CA3135381A1 (fr) * 2019-04-01 2020-10-08 Houn Simon Hsia Compositions et methodes pour l'immuno-cancerotherapie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU209973B (en) 1988-03-09 1995-01-30 Biorex Kutato Fejlesztoe Kft Process for production of antiviral and immunstimular pharmaceutical composition
HU199775B (en) * 1988-03-09 1990-03-28 Nagy Peter Literati Process for production of formed by fatty acids salts of amin acids and medical compositions containing them
HU210122B (en) * 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
EP0891771A1 (fr) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprenant du lysine et d'ascorbate ou ses dérivés pour le traitement de troubles cardiovasculaires
CA2313024C (fr) * 1997-12-10 2008-06-03 Severson, Mary L. Compositions pharmaceutiques contenant une huile d'acide gras omega-3
AT412758B (de) * 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
ATE555782T1 (de) * 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORI ET AL., AIDS RES. HUMAN RETROVIRUSES, vol. 13, 1997, pages 1325 - 32
J. AM. CHEM. SOC, vol. 59, 1982, pages 117

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073176A3 (fr) * 2005-12-23 2008-09-12 Nutricia Nv Composition permettant d'ameliorer la composition membranaire et le fonctionnement des cellules
US8546325B2 (en) 2005-12-23 2013-10-01 N.V. Nutricia Composition for improving membrane composition and functioning of cells
US20240148683A1 (en) * 2009-04-29 2024-05-09 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
EP3248467A1 (fr) * 2016-05-25 2017-11-29 Evonik Technochemie GmbH Procede de production d'une composition contenant des sels lysine-l-acides gras-omega 3
WO2017202935A1 (fr) * 2016-05-25 2017-11-30 Evonik Technochemie Gmbh Procédé de préparation d'une composition comprenant des sels d'acides gras oméga-3 et des amines
KR20190013895A (ko) * 2016-05-25 2019-02-11 에보닉 테크노케미 게엠베하 오메가-3 지방산 염 및 아민을 포함하는 조성물을 제조하는 방법
US11219235B2 (en) 2016-05-25 2022-01-11 Evonik Operations Gmbh Method for preparing a composition comprising omega-3 fatty acid salts and amines
EP4192483A4 (fr) * 2020-08-10 2024-08-21 Houn Simon Hsia Compositions et méthodes de traitement d'infection virale
AU2021324673B2 (en) * 2020-08-10 2025-07-24 Houn Simon Hsia Compositions and methods for treating viral infection

Also Published As

Publication number Publication date
WO2006059169A3 (fr) 2007-02-22
ATE429236T1 (de) 2009-05-15
DE602005014142D1 (de) 2009-06-04
US9381213B2 (en) 2016-07-05
HU227588B1 (hu) 2011-09-28
KR101263963B1 (ko) 2013-05-13
CA2588195C (fr) 2014-12-23
HU0402490D0 (en) 2005-02-28
KR20070086689A (ko) 2007-08-27
CN101068540B (zh) 2013-01-09
CA2588195A1 (fr) 2006-06-08
PL1830861T3 (pl) 2009-09-30
EP1830861A2 (fr) 2007-09-12
EP1830861B1 (fr) 2009-04-22
JP4976307B2 (ja) 2012-07-18
HUP0402490A2 (en) 2009-04-28
JP2008521877A (ja) 2008-06-26
DK1830861T3 (da) 2009-07-27
CN101068540A (zh) 2007-11-07
US20080131519A1 (en) 2008-06-05
ES2326091T3 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
Isaacs et al. Antiviral and antibacterial lipids in human milk and infant formula feeds.
EP0374390B1 (fr) Composition de protéines de petit lait, procédé de production et application de la composition de protéines de petit-lait
JP5474276B2 (ja) 高脂血症治療剤
CA1334576C (fr) Compositions pharmaceutiques antivirales et procede de preparation
EP0346451A1 (fr) Activite antivirale d'acides gras et de monoglycerides
JP4700808B2 (ja) フルボ酸、および種々の状態の処置におけるその使用
ES2228057T3 (es) Oregano para el tratamiento de parasitos internos y protozoos.
JPH02501743A (ja) ウイルス疾患のホスファチジル処置
JPS63218649A (ja) 抗酸化性アミノ酸系物質並びに該物質を主成分とする抗酸化剤
US9381213B2 (en) Antiviral and immune stimulant pharmaceutical composition
WO2020234884A1 (fr) Huile modifiée de larves de mouche soldat noire pourvue d'acide laurique modifié pour le traitement contre la formation de biofilm et la croissance de micro-organismes
RU2673807C2 (ru) Средство, обладающее биоцидным действием
BR112020020318A2 (pt) Composições para tratamento de pele
FI93949C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten suolayhdisteiden valmistamiseksi
WO2005068491A1 (fr) Peptides antitumoraux et antiviraux
EP0381823A2 (fr) Lipides moléculaires hétérogènes cytotropiques et leur procédé de préparation
CA2404322A1 (fr) Medicament pour stimuler la leucopoese, pour traiter des affections tumorales et des protozooses, l'acarinose, l'arthropodiase et procedes permettant de le produire
WO1993025208A1 (fr) Compositions d'acides gras spermicides et cytocides
HK1113910A (en) Antiviral and immunostimulating marine fish oil composition
JP4417273B2 (ja) 精子活性化剤および精子不活性化剤
JPH0748279A (ja) 後天性免疫不全症候群の治療法
Audit et al. Possible involvement of an acylation mechanism in thalidomide‐induced teratogenesis of the newt (Pleurodeles waltl.)
US4192896A (en) Method of using dialkylphenols in the treatment of mycoplasma diseases
Ahmed et al. The effect of salvia officinalis aqueous extract on generation number and time of leishmania tropica
AU611304B2 (en) Method of modifying the lipid structure of cell membranes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2588195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007543938

Country of ref document: JP

Ref document number: 200580041636.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005808584

Country of ref document: EP

Ref document number: 1020077014591

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11792247

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005808584

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11792247

Country of ref document: US